Date of Award
Dr. Lori Hensley
Dr. Angela Douglass
Dean Bryan McKinney
Acute promyelocytic leukemia (APL) is a cancer that affects bone marrow, the blood-forming tissue (of the body). This type of leukemia accounts for approximately 10% of acute myeloid leukemia (AML) cases. Normally this cancer is treated with a drug called all-trans retinoic acid (ATRA), but other variations of treatment do exist. The importance of this research is that APL cells express contains a receptor, retinoic acid receptor-a (RARa), which ajulemic acid (AJA) may bind to in order to induce apoptosis in Ewing sarcoma (ES), a pediatric bone cancer. Therefore, this research will focus on the ability of AJA to induce the differentiation of APL cells, as ATRA does, thus demonstrating that AJA may be binding to RARa.
Monk, Brian Christopher, "Acute Promyelocytic Leukemia as a Possible Source for Ajulemic Acid Binding" (2015). Honors Theses. 179.